Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 15, 2022
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
Mon, March 14, 2022
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $130 on, Mar 14th, 2022
Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $140 to $130 on, Mar 14th, 2022.
Raghuram has made no other calls on BTAI in the last 4 months.
There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Raghuram
- Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $25 on, Wednesday, February 16th, 2022
- Corinne Jenkins of "Goldman Sachs" Downgraded from Strong Buy to Strong Sell and Decreased Target to $24 on, Monday, November 15th, 2021
